Insulet (NASDAQ:PODD) had its price objective increased by equities researchers at Raymond James from $135.00 to $158.00 in a research report issued on Wednesday, AnalystRatings.com reports. The firm presently has an “outperform” rating on the medical instruments supplier’s stock. Raymond James’ price objective points to a potential downside of 6.76% from the company’s previous close.

Other analysts have also recently issued reports about the stock. BMO Capital Markets boosted their price objective on shares of Insulet from $130.00 to $150.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 6th. Piper Jaffray Companies restated an “overweight” rating and issued a $170.00 price objective (up from $160.00) on shares of Insulet in a research note on Wednesday. BidaskClub cut shares of Insulet from a “buy” rating to a “hold” rating in a research note on Tuesday. Cowen set a $165.00 price objective on shares of Insulet and gave the stock a “buy” rating in a research note on Monday, October 21st. Finally, Leerink Swann restated an “outperform” rating and issued a $185.00 price objective (up from $160.00) on shares of Insulet in a research note on Tuesday, September 24th. Ten research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $151.71.

Shares of Insulet stock opened at $169.46 on Wednesday. The firm has a fifty day simple moving average of $154.75 and a 200-day simple moving average of $130.77. The company has a current ratio of 4.72, a quick ratio of 3.91 and a debt-to-equity ratio of 2.43. Insulet has a 1-year low of $70.80 and a 1-year high of $171.96. The stock has a market capitalization of $8.73 billion, a price-to-earnings ratio of 3,389.20 and a beta of 0.96.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Tuesday, November 5th. The medical instruments supplier reported $0.01 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.03 by ($0.02). Insulet had a return on equity of 9.46% and a net margin of 2.38%. The firm had revenue of $192.12 million during the quarter, compared to analyst estimates of $179.50 million. During the same quarter in the previous year, the firm posted $0.03 earnings per share. Insulet’s quarterly revenue was up 27.2% compared to the same quarter last year. As a group, research analysts predict that Insulet will post 0.23 earnings per share for the current year.

In other Insulet news, SVP Michael P. Spears sold 4,153 shares of the business’s stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $146.12, for a total value of $606,836.36. Following the sale, the senior vice president now owns 22,626 shares of the company’s stock, valued at approximately $3,306,111.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Shacey Petrovic sold 649 shares of the business’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $152.40, for a total transaction of $98,907.60. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 5,491 shares of company stock valued at $806,124. Corporate insiders own 3.50% of the company’s stock.

Institutional investors have recently made changes to their positions in the business. Advisors Preferred LLC bought a new stake in Insulet in the 2nd quarter valued at $38,000. Harvest Fund Management Co. Ltd bought a new stake in Insulet in the 2nd quarter valued at $43,000. Mitsubishi UFJ Securities Holdings Co. Ltd. bought a new stake in Insulet in the 2nd quarter valued at $97,000. Steward Partners Investment Advisory LLC bought a new stake in Insulet in the 2nd quarter valued at $119,000. Finally, Cerebellum GP LLC bought a new stake in Insulet in the 3rd quarter valued at $122,000.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company offers Omnipod System, which consists of self-adhesive disposable tubeless Omnipod device (the pod) that delivers insulin into the body; and Personal Diabetes Manager, a handheld wireless device, which programs the Pod.

Read More: What are the benefits of investing in REITs?

Analyst Recommendations for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.